MedPath

Long-term Efficacy and Safety Study With Oralgen Grass Pollen

Phase 2
Completed
Conditions
Allergic Rhinoconjunctivitis
Interventions
Other: placebo
Registration Number
NCT00824447
Lead Sponsor
Artu Biologicals
Brief Summary

This study is designed to give additional information on the efficacy, safety and local effects (tolerability) of a dose of sublingual immunotherapy administered once a day, during a second grass pollen season.

Detailed Description

Allergy is one of the most common chronic diseases. Allergies to grass, weed, and tree pollens characteristically result in seasonal rhinitis symptoms commonly termed hay fever. The risk of developing asthma has been noted to be higher in patients with rhinitis than among the general population (10% versus 3.6%), confirming the fact that rhinitis is often the first step of the natural history of asthma.

Although several drugs effectively manage the symptoms of allergic rhinitis, conjunctivitis or asthma, they do not represent an etiopathogenic treatment of the considered diseases, and do not prevent the reappearance of the symptoms at the end of the treatment.

Immunotherapy is generally considered to be appropriate for patients in whom rhinitis symptoms cannot be controlled by an optimal medication regimen and avoidance of the allergens. At present, specific immunotherapy is the only therapy available that acts on the main cause of the allergic reaction by modifying or down-regulating the immune response.

Allergen immunotherapy is the administration of gradually increasing quantities of an allergen vaccine (extract) to an allergic subject, to reach a maintenance dose, which is effective in reducing the symptoms associated with exposure to the causative allergen.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
356
Inclusion Criteria
  • Patients who meet the in and exclusion criteria for study AB0602 and successfully finished this study.
  • Patients who have given their written consent to participate in this study.
  • Patients who are willing to comply with the protocol and understand the information given.
  • Female patients of childbearing potential are eligible if they are not sexually active or if they use a medically accepted contraceptive method.
  • Negative urine pregnancy test if female at the end of the previous study.
Exclusion Criteria
  • Pregnancy, breast-feeding / lactation or sexually active women of childbearing potential who are not using a medically accepted contraceptive method.
  • Patients who were non-compliant during study AB0602.
  • Patients with a past or current disease, which as judged by the investigator, may affect the patient's participation in or the outcome of this study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo controlplaceboPlacebo control
Grass pollen extract, twice weeklyOralgenGrass pollen extract, 9,500 BU, given twice weekly
Grass pollen extract dailyOralgenGrass pollen extract, 9,500 BU, given daily
Increased dose of grass pollen extractOralgenIncreased dose of grass pollen extract, 19,000 BU, given daily
Primary Outcome Measures
NameTimeMethod
Pollen Season Rhinoconjunctivitis Total Symptom Scoresite specific pollen season
Secondary Outcome Measures
NameTimeMethod
Rescue medication usageone year
Proportion of symptom-free days during the pollen seasonone year
Rhinoconjunctivitis QoL Questionnaireone year
Global evaluation of the efficacy by the patientone year
Local and systemic tolerability and other adverse events, laborone year

Trial Locations

Locations (36)

Nemocnice Caslav

🇨🇿

Caslav, Czech Republic

Alergologicka ambulance Okresni nemocnice Tabor

🇨🇿

Tabor, Czech Republic

Vilnius university hospital, Santariskiu Clinic

🇱🇹

Vilnius, Lithuania

Centrum imunologie a alergologie s.r.o

🇸🇰

Bratislava, Slovakia

Amb. klinickey imunologie a allergologie UTaRCH

🇸🇰

Poprad, Slovakia

Ambulancia klinickej imunologie a alergologie

🇸🇰

Trencin, Slovakia

Fakultni nemocnice Brno

🇨🇿

Brno-Bohunice, Czech Republic

Kaunas medical University hospital

🇱🇹

Kaunas, Lithuania

JSC Seimos gydytojas

🇱🇹

Vilnius, Lithuania

Ambulance plicni a alergologicka

🇨🇿

Ostrave - Hrabuvka, Czech Republic

Vilnius Central Outpatient Clinic

🇱🇹

Vilnius, Lithuania

Medcentrum s.r.o.

🇸🇰

Zilina, Slovakia

ORL Soukroma praxe

🇨🇿

Brno, Czech Republic

Alergologicka ordinace

🇨🇿

Kutna Hora, Czech Republic

MHAT PLovdiv, ENT Clinic

🇧🇬

Plovdiv, Bulgaria

5th MHAT, ENT Clinic

🇧🇬

Sofia, Bulgaria

Military Medical Academy, Clinic of ENT

🇧🇬

Sofia, Bulgaria

Ministry of interior-central clinical database

🇧🇬

Sofia, Bulgaria

Military Medical Academy

🇧🇬

Varna, Bulgaria

MHAT Sveta Marina

🇧🇬

Varna, Bulgaria

Alergologicka ambulance

🇨🇿

Ostrava - Hrabuvka, Czech Republic

Univ. klinikum Carl Gustav Carus

🇩🇪

Dresden, Germany

Berufsgen. kliniken Bergmannsheil

🇩🇪

Bochum, Germany

MedicoKIT

🇩🇪

Goch, Germany

Johannes-Gutenberg-Universitat Mainz

🇩🇪

Mainz, Germany

Karolina Korhaz

🇭🇺

Mosomagyarovar, Hungary

Vital Care

🇩🇪

Muenchen, Germany

Selye Janos Korhaz

🇭🇺

Komarom, Hungary

Privataertz. inst. & Forsh. einrichtung

🇩🇪

Wiesbaden, Germany

Szent Janos Korhaz

🇭🇺

Budapest, Hungary

Ampha Den Bosch / Regio Brabant

🇳🇱

's-Hertogenbosch, Netherlands

Ampha De Bilt

🇳🇱

De Bilt, Netherlands

AMPHA Nijmegen

🇳🇱

Nijmegen, Netherlands

Ampha

🇳🇱

Hengelo, Netherlands

Svabhegyi Allami Gyermekgyogyintezet pulmonologia

🇭🇺

Budapest, Hungary

Tudogyogyintezet Torokbalint

🇭🇺

Torokbalint, Hungary

© Copyright 2025. All Rights Reserved by MedPath